Short answer
Claritev Corp (CTEV) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for the quarter ended September 30, 2026 announced on November 9, 2026.
Claritev Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for the quarter ended September 30, 2026 announced on November 9, 2026
- Detailed financial results and management commentary available in Exhibit 99.1, the earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $268.3M, up 9.1%, signaling continued growth across Claritev’s healthcare technology offerings
- Net loss narrowed to $61.8M from $69.8M, but interest expense remained substantial at $100.9M
- Adjusted EBITDA $162.0M, up 4.4%, while margin fell to 60.4% from 63.1%, indicating weaker operating leverage
- Free cash flow worsened to negative $25.8M, with $44.4M of capital expenditures and only $10.1M unrestricted cash
- 2026 guidance raised: revenue $1.038B-$1.043B, Adjusted EBITDA $625M-$630M, free cash flow $10M-$20M; preliminary 2027 revenue expectation $1.1B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Claritev Corp 8-K filings
Get the next CTEV 8-K as it lands
Follow CTEV for push alerts, or ask the research agent what this filing means.